Background Halofuginone (HF) is a low-molecular-weight alkaloid that has been
demonstrated to interfere with Metalloproteinase-2 (MMP-2) and Tumor Growth Factor-β …

Promyelocytic leukemia-retinoic acid receptor alpha (PML-RARα) expression in acute
promyelocytic leukemia (APL) impairs transforming growth factor beta (TGFβ) signaling …

Tumor growth and metastasis depend on angiogenesis; therefore, efforts are made to
develop specific angiogenic inhibitors. Halofuginone (HF) is a potent inhibitor of collagen …

Halofuginone (HF) is extracted from Dichroa febrifuga, a plant used in traditional medicine.
We report that the HF extract inhibits the growth of breast cancer cells and induces the …

TGF-β derived from bone fuels melanoma bone metastases by inducing tumor secretion of
prometastatic factors that act on bone cells to change the skeletal microenvironment …

Osteosarcoma is the main malignant primary bone tumor in children and adolescents for
whom the prognosis remains poor, especially when metastases are present at diagnosis …

Halofuginone, a low-molecular-weight quinazolinone alkaloid that inhibits collagen α1 (I),
has been shown to suppress cancer growth, metastasis, and angiogenesis. These activities …

Malignant mesothelioma is a rare but aggressive form of malignancy, which is difficult to
diagnose and is resistant to current chemotherapeutic treatment options. Molecular …

Purpose It was reported that halofuginone has inhibitory effects on transforming growth
factor-beta (TGF-β) signaling pathway. The study was aimed to: 1) evaluate the antitumor …

Oral squamous cell carcinoma (OSCC) is the most common malignant tumor in the oral and
maxillofacial regions, with a high rate of metastasis. Cancer-associated fibroblasts (CAFs) …